

Insect Repellents

Selected References:

- Almeida AR, et al. (2023). Challenges encountered by natural repellents: Since obtaining until the final product. *Pestic Biochem Physiol.*195:105538.
- Barr DB, et al. 2010. Pesticide concentrations in maternal and umbilical cord sera and their relation to birth outcomes in a population of pregnant women and newborns in New Jersey. *Sci Total Environ* 408(4):790-795.
- Byrne S. 2016. Consumer Reports. Mosquito Repellents That Best Protect Against Zika. Available at: <http://www.consumerreports.org/insect-repellents/mosquito-repellents-that-best-protect-against-zika/>
- Diaz JH. 2016. Chemical and plant-based insect repellents: efficacy, safety, and toxicity. *Wilderness & Environmental Medicine* 27(1):153-63.
- Dugas J, et al. 2010. Use of biocides and insect repellents and risk of hypospadias. *Occup Environ Med* 67:196-200.
- Repellents: Protection against Mosquitoes, Ticks and Other Arthropods. Sept 14, 2021. Available at: <https://www.epa.gov/insect-repellents>. Accessed July 7, 2022.
- Fradin MS et al. 2002. Comparative efficacy of insect repellents against mosquito bites. *New Eng J of Med* 347.1: 13-18.
- Goodyer, L. et al. 2018. Mosquito repellents for the traveller: does picaridin provide longer protection than DEET? *J Travel Med* 25(suppl_1):S10.
- Lupi E, et al. 2013. The efficacy of repellents against *Aedes*, *Anopheles*, *Culex* and *Ixodes* spp.—a literature review. *Travel Med Infect Dis* 11(6):374-411.
- McGready R, et al. 2001. Safety of the insect repellent N,N-diethyl-M-toluamide (DEET) in pregnancy. *Am J Trop Med Hyg.* 65(4):285-9.
- Nguyen Q D, et al. 2018. Insect repellents: an updated review for the clinician. ***J of the Amer Acad of Derm.***
- Orders, M. 2021. Insect Repellents. *Med Lett Drugs Ther* 63(1628): 109-112.
- Segal TR, et al. 2017. Urinary concentrations of 3-(diethylcarbamoyl)benzoic acid (DCBA), a major metabolite of N,N-diethyl-m-toluamide (DEET) and semen parameters among men attending a fertility center. *Hum Reprod* 32(12):2532-2539.
- The American College of Obstetricians and Gynecologists (ACOG). 2019. Management of patients in the context of Zika virus. ACOG Committee Opinion, number 784. *Obstet Gynecol.* 134:e64.
- The U.S. Centers for Disease Control and Prevention (CDC). Prevent Mosquito Bites. Dec 2019. Available at: <https://www.cdc.gov/mosquitoes/prevention/?CDC> . Accessed August 2024.
- Wylie B., et al. 2016. Insect repellants during pregnancy in the era of the Zika Virus. *Obstetrics and Gynecology*; 128(5), 1111-1115.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 1, 2024.

Insect Repellents

Selected References:

- Amir LH, et al. 2006. A case-control study of mastitis: nasal carriage of Staphylococcus BMC Family Practice 7:57.
- Behari P, et al. 2004. Transmission of methicillin-resistant Staphylococcus aureus to preterm infants through breast milk. Infect Control Hosp Epidemiol 25(9):778-780.
- Briggs G. 2005. Drugs in Pregnancy and Lactation, a reference guide to fetal and neonatal risk. 7th Ed. Baltimore, MD: Williams & Williams.
- Centers for Disease Control and Prevention (CDC). 2024. About Staph food poisoning. <https://www.cdc.gov/staph-food-poisoning/about/index.html> [Accessed 8/2024].
- Centers for Disease Control and Prevention (CDC). 2024. Preventing Methicillin-resistant Staphylococcus aureus (MRSA): Prevent MRSA in higher risk settings. https://www.cdc.gov/mrsa/prevention/index.html#cdc_prevention_when_traveling-prevent-mrsa-in-higher-risk-settings [Accessed 8/2024].
- Centers for Disease Control and Prevention (CDC). 2024. Strategies to prevent hospital-onset Staphylococcus aureus bloodstream infections in acute care facilities. <https://www.cdc.gov/staphylococcus-aureus/hcp/prevent-in-acute-care-facilities/index.html> [Accessed 8/2024].
- De Rose, et al. 2023. Staphylococcal infections and neonatal skin: data from literature and suggestions for the clinical management from four challenging patients. Antibiotics. 12(4):632.
- Elston DM. 2007. Community acquired methicillin-resistant Staphylococcus aureus. J Am Acad Dermatol 56(1):1-16.
- Farsimadan M, Motamedifar M. 2020. Bacterial infection of the male reproductive system causing infertility. J Reprod Immunol. 142:103183.
- Frank A, et al. 1999. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Ped Inf Dis J 18:993-1000.
- Gastelum DT, et al. 2005. Transmission of community-associated methicillin-resistant Staphylococcus aureus from breast milk in the neonatal intensive care unit. Pediatr Infect Dis J. 24(12):1122-1124. 2
- Goto H, et al. 2003. Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics. Jpn J Antibiot. 58(3):326-58.
- Kawada M, et al. 2003. Transmission of Staphylococcus aureus between healthy, lactating mothers and their infants by breastfeeding. J Hum Lact 19(4):411- 417.
- Kriebs JM. 2016. Staphylococcus Infections in Pregnancy: Maternal and Neonatal Risks. J Perinat Neonatal Nurs. 30(2):115-23.
- Laibl V, et al. 2005. Clinical Presentation of Community-Acquired Methicillin-Resistant Staphylococcus aureus in Pregnancy. Obstet Gynecol 106 (3):461- 5.
- Leshem E et al. 2012. Transmission of Staphylococcus aureus from mothers to newborns. Pediatr Infect Dis J.

2012 Apr;31(4):360-3.

- Lazenby GB, et al. 2012. Methicillin-resistant *Staphylococcus aureus* colonization among women admitted for preterm delivery. *Am J Obstet Gynecol.* 206(4):329.e1-5.
- Maglio D, et al. 2005. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program. *Clin Ther.* 27(7):1032-42.
- Piva S, Mariella J, et al 2021. Epidemiologic case investigation on the zoonotic transmission of *Staphylococcus aureus* infection from goat to veterinarians. *Zoonoses Public Health.* 2021 Sep;68(6):684-690.
- Price M, et al. 1998. Prevalence of methicillin-resistant *Staphylococcus aureus* in a dermatology outpatient population. *South Med J* 91:369-71.
- Saravolatz L, et al. 1982. Methicillin-resistant *Staphylococcus aureus*: epidemiologic observations during a community-acquired outbreak. *Ann Intern Med.* 96:11-16.
- Sheffield JS. 2013. Methicillin-resistant *Staphylococcus aureus* in obstetrics. *Am J Perinatol.* 30(2):125-9.
- Younger Meek, American Academy of Pediatrics, et al. 2022. Policy Statement: Breastfeeding and the Use of Human Milk. *Pediatrics*; 150 (1): e2022057988.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 1, 2024.

Insect Repellents

- Agrawal M, et al. 2022. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis. *Clinical endocrinology*, 96(6):857-868.
- Akmal A, Kung J. 2014. Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity. *Expert Opin Drug Saf*, 13(10):1397-1406.
- Alexander EK, et al. 2017. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. *Thyroid: official journal of the American Thyroid Association*, 27(3):315-389.
- American College of Obstetricians and Gynecology. 2020. Thyroid disease in pregnancy. *ACOG Practice Bulletin*,

Number 223. *Obstet Gynecol*, 135(6):e261-e274.

- Andersen SL, et al. 2013. Birth Defects after early pregnancy use of antithyroid drugs: A Danish nationwide study. *J Clin Endocrinol Metab*, 98(11):4374-4381.
- Andersen SL, et al. 2017. Birth Defects after early pregnancy use of antithyroid drugs: A Swedish nationwide study. *Euro J Endocrinol*, 177(4):369-378.
- Andersen SL, Andersen S. 2020. Antithyroid drugs and birth defects. *Thyroid Res*, 13:11.
- Arata N, et al. 2012. Pregnancy outcomes of exposure to methimazole (POEM) study: an interim report. *Japanese journal of clinical medicine*, 70(11):1976-1982.
- Awosika AO, et al. 2023. Methimazole. StatPearls [Internet], Treasure Island (FL), available from: <https://www.ncbi.nlm.nih.gov/books/NBK545223/>
- Azizi F. 2003. Thyroid function in breast-fed infants is not affected by methimazole-induced maternal hypothyroidism: results of a retrospective study. *J Endocrinol Invest*, 26:301-304.
- Baid SK, Merke DP. 2007. Aplasia cutis congenita following in utero methimazole exposure. *J Pediatr Endocrinol Metab*, 20:585-586.
- Barbero P, et al. 2008. Choanal atresia associated with maternal hyperthyroidism treated with methimazole: a case-control study. *Am J Med Genet*, 146A(18):2390-2395.
- Cassina M, et al. 2012. Pharmacologic treatment of hyperthyroidism during pregnancy. *Birth Defects Res A Clin Mol Teratol*, 94(8):612-619.
- Chan GW, Mandel SJ. 2007. Therapy insight: management of Graves' disease during pregnancy. *Nat Clin Pract Endocrinol Metab*; 3(6):470-8.
- Chen CH, et al. 2011. Risk of adverse perinatal outcomes with antithyroid treatment during pregnancy: a nationwide population-based study. *BJOG*, 118:1365-1373.
- Clementi M, et al. 1999. Methimazole embryopathy: delineation of the phenotype. *Am J Med Genet*, 83:43-46.
- Committee on Drugs, American Academy of Pediatrics. 2001. The transfer of drugs and other chemicals into human breast milk. *Pediatrics*, 108:776-789.
- Cooper DS. 1987. Antithyroid drugs: to breast-feed or not to breast-feed. *Am J Obstet Gynecol*, 157:234-235.
- Diav-Citrin O, Ornoy A. 2002. Teratogen update: antithyroid drugs-methimazole, carbimazole, and propylthiouracil. *Teratology*, 65:38-44.
- Di Gianantonio E, et al. 2001. Adverse effects of prenatal methimazole exposure. *Teratology*, 64(5):262-266.
- Dumi M, et al. 2002. Choanal stenosis, hypothelia, deafness, recurrent dacryocystitis, neck fistulas, short stature, and microcephaly: report of a case. *Am J Med Genet*, 113:295-297.
- Dumitrascu MC, et al. 2021. Hyperthyroidism management during pregnancy and lactation (Review). *Exp Ther Med*, 22(3):960.
- Eisenstein Z, et al. 1992. Intellectual capacity of subjects exposed to methimazole or propylthiouracil in utero. *Eur J Pediatr*, 151:558-559.
- Ferraris S, et al. 2003. Malformations following methimazole exposure in utero: an open issue. *Birth Defects Res (Part A)*, 67:989-992.
- Francis T, et al. 2020. Safety of antithyroid drugs in pregnancy: update and therapy implications. *Expert Opin Drug Saf*, 19(5):565-576.
- Gianetti E, et al. 2015. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy. *J Endocrinol Invest*, 38(9):977-985.
- Greenberg F. 1987. Brief clinical report: Choanal atresia and athelia: Methimazole teratogenicity or a new syndrome? *Am J Med Genet*, 28:931-934.
- Gripp KW, et al. 2011. Grade 1 microtia, wide anterior fontanel and novel type trachea-esophageal fistula in methimazole embryopathy. *Am J Med Genet A*, 155A(3):526-533.
- Howley MM, et al. 2017. Thyroid medication use and birth defects in the National Birth Defects Prevention Study. *Birth Defects Res*, 109(18):1471-1481.
- Hudzik B, Zubelewicz-Szkodzinska B. 2016. Antithyroid drugs during breastfeeding. *Clin Endocrinol (Oxf)*,

85(6):827-830.

- Johnsson E, et al. 1997. Severe malformations in infant born to hyperthyroid woman on methimazole. *Lancet*, 350:1520.
- Karlsson FA, et al. 2002. Severe embryopathy and exposure to methimazole in early pregnancy. *J Clin Endocrinol Metab*, 87(2):947-949.
- Korelitz JJ, et al. 2013. Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. *Thyroid*, 23:758-765.
- Martin-Denavit T, et al. 2000. Ectodermal abnormalities associated with methimazole intrauterine exposure [letter]. *Am J Med Genet*, 94:338-340.
- Methimazole tablets, USP Prescribing Information. Par Pharmaceutical Companies, Inc. Spring Valley, NY 10977. Accessed May 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/040350s016lbl.pdf
- Mitsuda N, et al. 1992. Risk factors for developmental disorders in infants born to women with Graves disease. *Obstet Gynecol*; 80(3 Pt 1):359-64.
- Momotani M, et al. 1984. Maternal hyperthyroidism and congenital malformation in the offspring. *Clin Endocrinol (Oxford)*, 20:695-700.
- Purnamasari D, et al. 2019. Gastroschisis Following Treatment with High-Dose Methimazole in Pregnancy: A Case Report. *Drug Saf Case Rep*, 6(1):5.
- Radetti G, et al. 2002. Foetal and neonatal thyroid disorders. *Minerva Pediatr*; 54(5):383-400.
- Rasmussen SA, et al. 2007. Maternal thyroid disease as a risk factor for craniosynostosis. *Obstetrics and gynecology*, 110(2 Pt 1):369-377.
- Romeo AF, Obican SG. 2020. Teratogen Update: Antithyroid Medications. *Birth Defects Res*, 112(15):1150-1170.
- Sargent KA, et al. 1994. Apparent scalp-ear-nipple (Findlay) syndrome in a neonate exposed to methimazole in-utero. *Am J Hum Genet*, 55:A312.
- Sato Y, et al. 2014. A case of fetal hyperthyroidism treated with maternal administration of methimazole. *J Perinatol*, 34(12):945-347.
- Seo GH, et al. 2018. Antithyroid drugs and congenital malformations. A nationwide Korean cohort study. *Ann Intern Med*, 168(6):405-413.
- Seoud M, et al. 2003. Gastrointestinal malformations in two infants born to women with hyperthyroidism untreated in the first trimester. *Am J Perinatol*, 20:59-62.
- Shepard TH, et al. 2002. Update on new developments in the study of human teratogens. *Teratology*, 65(4):153-161.
- Stagnaro-Green A, et al. 2011. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. *Thyroid*, 21:1081-1125.
- Tegler L, Lindstrom B. 1980. Antithyroid drugs in milk. *Lancet*, 2:591.
- The WHO Working Group, Bennet PN (ed). 1988. *Drugs and Human Lactation*. Elsevier, Amsterdam, New York, Oxford, pp. 196-197.
- Tonacchera M, et al. 2020. Treatment of Graves' hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy. *J Endocrinol Invest*, 43(2):257-265.
- Wilson LC, et al. 1998. Choanal atresia and hypothelia following methimazole exposure in utero: a second report. *Am J Med Genet*, 75:220-222.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 1, 2024.

Insect Repellents

Selected References:

- Centers for Disease Control and Prevention. 2008. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 57(RR07):1-60.
- Centers for Disease Control and Prevention. 2024. Clinical Overview of Evaluating and Managing Patients Exposed to Birds Infected with Avian Influenza A Viruses of Public Health Concern. Available at: https://www.cdc.gov/bird-flu/hcp/clinicians-evaluating-patients/?CDC_AAref_Val=https://www.cdc.gov/flu/avianflu/clinicians-evaluating-patients.htm. Accessed 28 June 2024.
- Centers for Disease Control and Prevention. 2024. Current U.S. Bird Flu Situation in Humans. Available at: <https://www.cdc.gov/bird-flu/situation-summary/inhumans.html>. Accessed 28 June 2024.
- Centers for Disease Control and Prevention. 2024. Highly Pathogenic Avian Influenza A(H5N1) Virus in Animals: Interim Recommendations for Prevention, Monitoring, and Public Health Investigations. Available at: <https://www.cdc.gov/bird-flu/prevention/hpai-interim-recommendations.html>. Accessed 28 June 2024.
- Centers for Disease Control and Prevention. 2024. Prevention and Antiviral Treatment of Avian Influenza A Viruses in People. Available at: <https://www.cdc.gov/bird-flu/prevention/index.html>. Accessed 28 June 2024.
- Centers for Disease Control and Prevention. 2024. Reducing Risk for People Working with or Exposed to Animals. Available at: <https://www.cdc.gov/bird-flu/prevention/worker-protection-ppe.html>. Accessed 28 June 2024.
- Fiore AE et al. 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 59(RR-8):1-62. Erratum: Vol . 59, No. RR-8.
- Gu J, et al. 2007. H5N1 infection of respiratory tract and beyond: a molecular pathology study. Lancet 370:1137-1145.
- Le TV, et al. 2019. Fatal avian influenza A(H5N1) infection in a 36-week pregnant woman survived by her newborn in Sóc Trăng Province, Vietnam, 2012. Influenza Other Respir Viruses 13(3):292-297.
- Liu S, et al. 2016. Avian influenza virus in pregnancy. Rev Med Virol 26(4):268-284.
- Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. 2008. Update on Avian Influenza A (H5N1) Virus Infection in Humans. N Engl J Med 358(3):261-273.
- Zaman K, et al. 2008. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 359(15):1555-64.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 1, 2024.

Insect Repellents

Selected References:

- Barr M Jr, Cohen MM Jr. 1991. ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection. *Teratology*, 44:485-495.
- Bhatt-Mehta V, Deluga KS. 1993. Fetal exposure to lisinopril: neonatal manifestations and management. *Pharmacotherapy*, 13(5): 515-518.
- Burrows RF, Burrows EA. 1998. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. *Aust N Z J Obstet Gynaecol*, 38(3):306-311.
- Cooper WO, et al. 2006. Major congenital malformations after first-trimester exposure to ACE inhibitors. *N Engl J Med*, 354(23): 2443-2451.
- Diav-Citrin O, et al. 2011. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. *Reprod Toxicol*, 31(4):540-545.
- Filler G, et al. 2003. Early dialysis in a neonate with intrauterine lisinopril exposure. *Arch Dis Child Fetal Neonatal Ed*, 88(2):F154-156.
- Friedman JM. 2006. ACE inhibitors and congenital anomalies. *N Engl J Med*, 354:2498-2500.
- Karthikeyan VJ, et al. 2011. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. *J Hypertens*, 29(2):396-399.
- Lennestall R, et al. 2009. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. *Eur J Clin Pharmacol*, 65(6):615-625.
- Lip GYH, et al. 1997. Angiotensin-converting-enzyme inhibitors in early pregnancy. *Lancet*, 350:1446-1447.
- Merck Sharp and Dohme Corp. 2018. Prinivil product label.
- Moretti ME, et al. 2012. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. *Obstet Gynecol Int*.
- National Collaborating Centre for Women's and Children's Health (UK). 2011. Hypertension in Pregnancy. Appendix O. Safety of commonly used antihypertensive drugs during breastfeeding. NICE Clinical Guidelines, No. 107. London: RCOG Press.
- Polifka JE. 2012. Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence. *Birth Defects Res (Part A)*, 94:576-598.
- Pryde PG, et al. 1993. Angiotensin-converting enzyme inhibitor fetopathy. *J Am Soc Nephrol*, 3:1575-1582.
- Rosa F, Bosco L. 1991. Infant renal failure with maternal ACE inhibition. *Am J Obstet Gynecol*, 161(1 Part 2):273 (abstract).
- Tomlinson AJ, et al. 2000. Malignant primary hypertension in pregnancy treated with lisinopril. *Ann Pharmacother*, 34(2):180-182.
- U.S. Food and Drug Administration (FDA). 1992. Upgraded warning on the use of ACE inhibitors during

pregnancy.

- Yip SK, et al.1998. Exposure to angiotensin-converting enzyme inhibitors during first trimester: is it safe to fetus? Acta Obstet Gynecol Scand, 77:570-571.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 1, 2024.